Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539).
1. What are the unmet needs in the treatment of episodic migraine? (0:05)
2. Could you tell us a little about the objectives and design of the HER-MES study of erenumab vs topiramate? (1:13)
3. What have been the findings of the study so far? (3:10)
4. What has been the impact of antibodies targeting calcitonin gene-related peptide (CGRP) on the treatment landscape for episodic migraine? (4:44)
5. How do you see the treatment of episodic migraine progressing in the next 5 years? (6:50)
Speaker disclosure: Uwe Reuter reports having received honoraria for consulting and lectures within the past 3 years from Amgen, PharmAllergan, Eli Lilly, Lundbeck, Novartis Pharma, Hormosan Pharma, electroCore, Medscape, Novartis, StreaMedUp and Teva, he holds no stocks of pharmaceutical companies or medical device companies.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Headache Disorders
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!